Notable Labs Ltd. (NTBLQ)

Overview

Notable Labs, Ltd. is a forward-looking biotechnology firm founded in 2014, focusing on the development of predictive precision medicines aimed at combating cancer. The company is dedicated to revolutionizing cancer treatment through its proprietary Predictive Precision Medicines Platform (PPMP). This innovative platform offers a bio-simulation of cancer treatments, providing predictions on patient responses to their actual treatment regimens. Based in Foster City, California, Notable Labs, Ltd. is pioneering the approach of selecting clinically responsive patients ahead of treatment, which has the potential to significantly accelerate therapeutic development for those patients.

Products and Services

The company’s dedication to transforming cancer treatment is evident through its development of promising therapies and technologies:

• Volasertib:

  As a potent inhibitor of Polo-like kinase 1 (PLK-1), Volasertib is at the forefront of Notable Labs' innovative pipeline. It's designed to induce cell cycle arrest and apoptosis in various cancer cells, showing promise in the fight against cancer by targeting one of the key regulators of cell division.

• Fosciclopirox:

  A pro-drug of ciclopirox, Fosciclopirox is being developed specifically for the treatment of acute myeloid leukemia (AML). This compound represents Notable Labs' strive towards providing targeted, effective treatments for some of the most challenging types of cancer. The ambition behind Fosciclopirox shows the company’s commitment to expanding its range of cancer therapies, aiming to meet the urgent needs of patients suffering from AML.